Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Table 5 Clinical parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup

	Increased LDL-C group (n = 20)				Decreased LDL-C group (n = 20)				p values^b	p values^c
	Pre treatment	Post treatment	% change	p values^a	Pre treatment	Post treatment	% change	p values^a	p values^b	p values^c
Age (years)	51.6 ± 8.2				56.9 ± 7.8				0.047*
BW (kg)	78.8 ± 14.3	76.8 ± 15.4	−2.5	0.002*	78.0 ± 14.7	75.5 ± 14.5	−3.2	0.001*	0.853	0.394
AST (IU/L)	36.1 ± 22.3	29.4 ± 15.9	−18.6	<0.001*	32.7 ± 16.3	24.1 ± 7.7	−26.3	0.002*	0.596	0.622
ALT (IU/L)	52.5 ± 46.1	39.9 ± 31.9	−24.0	0.032*	40.4 ± 23.6	26.7 ± 11.7	−33.9	0.030*	0.312	0.874
γGTP (IU/L)	51.0 ± 40.5	50.3 ± 62.6	−1.4	0.930	55.5 ± 46.5	34.0 ± 20.4	−38.7	0.030*	0.750	0.119
BUN (mg/dL)	14.1 ± 3.8	16.3 ± 4.3	15.6	0.013*	15.1 ± 4.9	17.3 ± 5.8	14.6	0.010*	0.470	0.996
Cre (mg/dL)	0.71 ± 0.15	0.72 ± 0.17	1.4	0.700	0.72 ± 0.19	0.77 ± 0.29	6.9	0.170	0.964	0.258
eGFR (mL/min/1.73 m²)	89.0 ± 18.8	88.0 ± 17.6	−1.1	0.661	83.3 ± 18.1	81.7 ± 22.1	−1.9	0.507	0.342	0.861
FPG (mg/dL)	152 ± 46	127 ± 27	−16.4	0.006*	138 ± 50.1	116 ± 21	−15.9	0.040*	0.382	0.815
HbA1c (%)	7.51 ± 1.1	6.92 ± 0.94	−7.9	0.002*	7.72 ± 1.1	6.81 ± 0.67	−11.8	<0.001*	0.575	0.225
CPR index	2.77 ± 15.2	2.35 ± 1.28	−15.2	0.008*	2.82 ± 1.28	2.44 ± 1.82	−13.4	0.243	0.922	0.486
Adiponectin (ng/mL)	5.5 ± 3.8	7.2 ± 5.4	30.9	0.002*	6.5 ± 2.8	8.0 ± 2.6	23.1	0.001*	0.383	0.675

Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
BW body weight, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, BUN blood urea nitrogen, Cre creatinine, FPG fasting plasma glucose, LDL-C low-density lipoprotein-cholesterol
^ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
^bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
^cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)

ISSN: 1475-2840